While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Leerink Partners analyst Mani Foroohar has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Invest with ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

Concerns about the safety and efficacy of mRNA COVID-19 shots have increased after a January 3 report that drug maker Moderna failed to inform the U.S. government of the death of a child during ...

Shares of Moderna are down 90%, and the company has a huge cash pile after the COVID-19 pandemic. The maker of vaccines, including the mRNA vaccine for COVID-19, is amid a 90% stock price downturn.

Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical ... it is the cause of about half of all foodborne disease outbreaks. Covid-19: US clears Johnson & Johnson's shot ...